Stock Financial Ratios, Dividends, Split History

KEM / KEMET Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price28.91
Volume1,226,900.00
Market Cap ($M)1,605.82
Enterprise Value ($M)1,643.60
Book Value ($M)462.96
Book Value / Share8.13
Price / Book3.47
NCAV ($M)-78.84
NCAV / Share-1.38
Price / NCAV-20.37
Share Statistics
Common Shares Outstanding 56,944,132
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)n/a
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Assets1,218.27
Liabilities755.31
Quick Ratio1.66
Current Ratio2.37
Income Statement (mra) ($M)
Revenue From Grants800,000.00
Discontinued Operations Disposal Group Revenue0.00
Sales Revenue Goods Net1,199,926,000.00
Operating Income113.30
Earnings Per Share Diluted4.34
Earnings Per Share Basic4.82
Cash Flow Statement (mra) ($M)
Cash From Operations120.86
Cash from Investing102.36
Cash from Financing120.86
Identifiers and Descriptors
CUSIP488360207
Central Index Key (CIK)887730
Related CUSIPS
488360957 488360907

Split History

Stock splits are used by KEMET Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

10 Small-Caps Leading the Market Rebound 

2018-07-10 investorplace
Stocks are blitzed higher Monday, pushing the Dow Jones Industrial Average back up and over its 50-day moving average, as investors continue to respond to Friday’s “Goldilocks” payroll report. (14-2)

Should WisdomTree U.S. SmallCap Earnings Fund (EES) Be on Your Investing Radar?

2018-07-06 zacks
If you're interested in broad exposure to the Small Cap Value segment of the US equity market, look no further than the WisdomTree U.S. SmallCap Earnings Fund (EES - Free Report) , a passively managed exchange traded fund launched on 02/23/2007. (6-1)

Earnings or Revenue-Weighted ETFs: Who Won in Q1?

2018-06-12 zacks
We are at the end of the Q1 earnings season. As of now, 98.6% of the S&P 500 companies have reported earnings for Q1, with a 24.3% year-over-year jump on 8.7% revenue growth. Almost 76.9% of the companies beat on earnings while 74.4% beat on revenues, per the Earnings Trends issued on May 31. (103-0)

Should WisdomTree U.S. SmallCap Earnings Fund (EES) Be on Your Investing Radar?

2018-06-12 zacks
Launched on 02/23/2007, the WisdomTree U.S. SmallCap Earnings Fund (EES - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Value segment of the US equity market. (50-0)

Is the Options Market Predicting a Spike in KEMET (KEM) Stock?

2018-06-08 zacks
Investors in KEMET Corporation (KEM - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because Jun 15, 2018 $16 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. (153-0)

CUSIP: 488360207